NeuroSense Therapeutics Ltd. (NRSN) Stock Ticker
Market factors today
Unlock the full NRSN picture
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
NRSN stock facts
| Ticker symbol | NRSN |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $9.0M |
| CEO | Alon Ben-Noon |
| Employees | 17 |
| Headquarters | Herzliya, TA, IL |
| IPO date | 2021-12-09 |
| Website | www.neurosense-tx.com |
What you can see for NRSN on Tickr
Live NRSN price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the NRSN report.
Rankings
FAQ
What is the ticker symbol for NeuroSense Therapeutics Ltd.?
The ticker symbol for NeuroSense Therapeutics Ltd. is NRSN, listed on the NASDAQ Capital Market.
What is NRSN?
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of…